170 related articles for article (PubMed ID: 23265712)
1. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
[TBL] [Abstract][Full Text] [Related]
2. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.
Shiah HS; Chen CY; Dai CY; Hsiao CF; Lin YJ; Su WC; Chang JY; Whang-Peng J; Lin PW; Huang JD; Chen LT
Aliment Pharmacol Ther; 2013 Jan; 37(1):62-73. PubMed ID: 23134470
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma.
Furuse J; Okusaka T; Kaneko S; Kudo M; Nakachi K; Ueno H; Yamashita T; Ueshima K
Cancer Sci; 2010 Dec; 101(12):2606-11. PubMed ID: 20946314
[TBL] [Abstract][Full Text] [Related]
8. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
[TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma.
Cheng AL; Yeh KH; Fine RL; Chuang SE; Yang CH; Wang LH; Chen DS
Hepatogastroenterology; 1998; 45(24):1955-60. PubMed ID: 9951847
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Sun W; Sohal D; Haller DG; Mykulowycz K; Rosen M; Soulen MC; Caparro M; Teitelbaum UR; Giantonio B; O'Dwyer PJ; Shaked A; Reddy R; Olthoff K
Cancer; 2011 Jul; 117(14):3187-92. PubMed ID: 21264839
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors.
Rosen PJ; Sweeney CJ; Park DJ; Beaupre DM; Deng H; Leitch IM; Shubhakar P; Zhu M; Oliner KS; Anderson A; Yee LK
Clin Cancer Res; 2010 May; 16(9):2677-87. PubMed ID: 20406832
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepatocellular carcinoma.
Govindarajan R; Siegel E; Makhoul I; Williamson S
Am J Clin Oncol; 2013 Jun; 36(3):254-7. PubMed ID: 22643560
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
16. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics.
Yau T; Chen PJ; Chan P; Curtis CM; Murphy PS; Suttle AB; Gauvin J; Hodge JP; Dar MM; Poon RT
Clin Cancer Res; 2011 Nov; 17(21):6914-23. PubMed ID: 21831954
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Petrini I; Lencioni M; Ricasoli M; Iannopollo M; Orlandini C; Oliveri F; Bartolozzi C; Ricci S
Cancer Chemother Pharmacol; 2012 Mar; 69(3):773-80. PubMed ID: 22033636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]